Peter Arvidsson

671 total citations
17 papers, 519 citations indexed

About

Peter Arvidsson is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Immunology and Allergy. According to data from OpenAlex, Peter Arvidsson has authored 17 papers receiving a total of 519 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Physiology, 13 papers in Pulmonary and Respiratory Medicine and 6 papers in Immunology and Allergy. Recurrent topics in Peter Arvidsson's work include Asthma and respiratory diseases (16 papers), Respiratory and Cough-Related Research (9 papers) and Inhalation and Respiratory Drug Delivery (8 papers). Peter Arvidsson is often cited by papers focused on Asthma and respiratory diseases (16 papers), Respiratory and Cough-Related Research (9 papers) and Inhalation and Respiratory Drug Delivery (8 papers). Peter Arvidsson collaborates with scholars based in Sweden, Switzerland and Denmark. Peter Arvidsson's co-authors include Jan Lötvall, Mona Palmqvist, S Larsson, CG Lofdahl, L. Wåhlander, B Melander, N Svedmyr, Stefan Peterson, Ola Beckman and Alan Maloney and has published in prestigious journals such as PLoS ONE, American Journal of Respiratory and Critical Care Medicine and Journal of Allergy and Clinical Immunology.

In The Last Decade

Peter Arvidsson

17 papers receiving 489 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Arvidsson Sweden	10	476	408	94	87	30	17	519
EH Bel Netherlands	7	413 0.9×	353 0.9×	20 0.2×	70 0.8×	6 0.2×	16	458
A Knight Canada	13	305 0.6×	231 0.6×	35 0.4×	162 1.9×	73 2.4×	17	460
John Given United States	6	304 0.6×	227 0.6×	9 0.1×	138 1.6×	19 0.6×	10	343
R. Townley United States	7	275 0.6×	245 0.6×	8 0.1×	53 0.6×	6 0.2×	16	348
M. Grosclaude France	10	290 0.6×	84 0.2×	19 0.2×	265 3.0×	121 4.0×	28	385
Theo A. Bantje Netherlands	8	403 0.8×	391 1.0×	8 0.1×	31 0.4×		9	435
Nicoletta M. Azzolin Italy	8	581 1.2×	512 1.3×	5 0.1×	94 1.1×	3 0.1×	10	671
Donna Reilly United States	6	243 0.5×	269 0.7×	8 0.1×	16 0.2×	2 0.1×	13	308
Pekka Saarelainen Finland	5	317 0.7×	302 0.7×	4 0.0×	32 0.4×	4 0.1×	6	355
A. J. M. Schreurs Netherlands	8	245 0.5×	299 0.7×	16 0.2×	11 0.1×		19	378

Countries citing papers authored by Peter Arvidsson

Since Specialization

Citations

This map shows the geographic impact of Peter Arvidsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Arvidsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Arvidsson more than expected).

Fields of papers citing papers by Peter Arvidsson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Arvidsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Arvidsson. The network helps show where Peter Arvidsson may publish in the future.

Co-authorship network of co-authors of Peter Arvidsson

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Arvidsson. A scholar is included among the top collaborators of Peter Arvidsson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Arvidsson. Peter Arvidsson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Pfaar, Oliver, Hendrik Wolf, André C. Knulst, et al.. (2024). Treatment with the SQ tree sublingual immunotherapy tablet is safe and well tolerated in real‐life. Clinical and Translational Allergy. 14(7). e12373–e12373. 2 indexed citations

Sidenius, K, et al.. (2021). A Real-Life One-Year Non-Interventional Study Assessing Safety, Tolerability, and Treatment Outcome of the SQ HDM SLIT-Tablet (Acarizax®) in House Dust Mite Allergic Rhinitis With or Without Asthma. Pulmonary Therapy. 7(1). 221–236. 8 indexed citations

Kiotseridis, Hampus, et al.. (2018). Adherence and quality of life in adults and children during 3-years of SLIT treatment with Grazax—a real life study. npj Primary Care Respiratory Medicine. 28(1). 4–4. 24 indexed citations

Janson, Christer, et al.. (2018). Sublingual grass allergen specific immunotherapy: a retrospective study of clinical outcome and discontinuation. Clinical and Molecular Allergy. 16(1). 14–14. 9 indexed citations

Sundblad, Britt‐Marie, Sven‐Arne Jansson, Lennarth Nyström, et al.. (2013). Chronic Obstructive Pulmonary Disease (COPD) During the Two Last Years of Life – A Retrospective Study of Decedents. PLoS ONE. 8(12). e84110–e84110. 3 indexed citations

Lötvall, Jan, Mona Palmqvist, & Peter Arvidsson. (2011). Comparing the effects of two inhaled glucocorticoids on allergen‐induced bronchoconstriction and markers of systemic effects, a randomised cross‐over double‐blind study. Clinical and Translational Allergy. 1(1). 12–12. 1 indexed citations

Palmqvist, Mona, C.Allen Bruce, Margareta Sjöstrand, Peter Arvidsson, & Jan Lötvall. (2004). Differential effects of fluticasone and montelukast on allergen‐induced asthma. Allergy. 60(1). 65–70. 32 indexed citations

Chapman, Kenneth R., et al.. (2002). The Addition of Salmeterol 50 µg Bid to Anticholinergenic Treatment in Patients with COPD: A Randomized Placebo Controlled Trial. Canadian Respiratory Journal. 9(3). 178–185. 50 indexed citations

Palmqvist, Mona, Peter Arvidsson, Ola Beckman, Stefan Peterson, & Jan Lötvall. (2001). Onset of Bronchodilation of Budesonide/Formoterol vs. Salmeterol/Fluticasone in Single Inhalers. Pulmonary Pharmacology & Therapeutics. 14(1). 29–34. 90 indexed citations

10.

Lötvall, Jan, Mona Palmqvist, Peter Arvidsson, et al.. (2001). The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. Journal of Allergy and Clinical Immunology. 108(5). 726–731. 76 indexed citations

11.

Arvidsson, Peter, C.-G. Löfdahl, Bengt‐Eric Skoogh, & Jan Lötvall. (2001). Exudation of plasma and production of thromboxane in human bronchi after local bradykinin challenge. Respiratory Medicine. 95(5). 313–318. 4 indexed citations

12.

Arvidsson, Peter, Á. Callejo Mellén, Mona Palmqvist, & Jan Lötvall. (2000). Equivalent therapeutic ratio of salbutamol given by Turbuhaler®and Diskus™. Respiratory Medicine. 94(6). 574–577. 10 indexed citations

13.

Mellén, Á. Callejo, Peter Arvidsson, Mona Palmqvist, & Jan Lötvall. (1999). Equivalent Bronchodilation with Salbutamol Given via pMDI or Turbuhaler. American Journal of Respiratory and Critical Care Medicine. 159(5). 1663–1665. 21 indexed citations

14.

Lötvall, Jan, Á. Callejo Mellén, Peter Arvidsson, et al.. (1999). Similar Bronchodilation with Formoterol Delivered by Aerolizer or Turbuhaler. Canadian Respiratory Journal. 6(5). 412–416. 23 indexed citations

15.

Arvidsson, Peter, S Larsson, & C.-G. Löfdahl. (1993). Objective and Subjective Bronchodilation over 12 Hours After Inhaled Formoterol: Individual Responses. Journal of Asthma. 30(6). 459–465. 7 indexed citations

16.

Arvidsson, Peter, S Larsson, CG Lofdahl, et al.. (1991). Inhaled formoterol during one year in asthma: a comparison with salbutamol. European Respiratory Journal. 4(10). 1168–1173. 82 indexed citations

17.

Arvidsson, Peter, S Larsson, CG Lofdahl, et al.. (1989). Formoterol, a new long-acting bronchodilator for inhalation. European Respiratory Journal. 2(4). 325–330. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact